JAK2 Inhibitor Crystalline Forms for Solubility and Formulation Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective protein kinase inhibitors to treat diseases associated with abnormal cellular responses, particularly myeloproliferative disorders such as myelofibrosis and essential thrombocythemia.
Innovation Solution
The development of crystalline forms of Compound 1, which can inhibit JAK2 kinase activity and are formulated with various co-formers such as acids and salts, providing therapeutic agents for treating myeloproliferative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If crystalline forms of Compound 1 are developed with various co-formers, then the therapeutic effectiveness and solubility are improved, but the formulation complexity increases
Solution Approach 1:
The patent applies parameter changes by developing multiple crystalline forms (polymorphs) of Compound 1 with different physical and chemical parameters. Each crystalline form exhibits distinct solubility, stability, and bioavailability characteristics, allowing optimization of therapeutic effectiveness while managing formulation complexity through systematic variation of crystal structure parameters
Solution Approach 2:
The patent employs composite materials by formulating Compound 1 with various co-formers including acids (hydrobromic acid, sulfuric acid, toluenesulfonic acid), salts, and other compounds to create complex formulations. These composite formulations enhance therapeutic effectiveness by improving solubility and stability, while the systematic approach to selecting co-formers helps manage overall formulation complexity
2Ease of operation
If multiple crystalline forms and complexes are developed, then the solubility and bioavailability are improved, but the manufacturing process complexity increases
Solution Approach 1:
The patent applies segmentation by separating the development into distinct crystalline forms and complexes, each with optimized solubility characteristics. This segmentation allows for targeted manufacturing processes for each form, reducing overall manufacturing complexity by treating each crystalline form as a discrete product with its own optimized production pathway
Solution Approach 2:
The patent uses parameter changes to develop crystalline forms with improved solubility and bioavailability by varying crystal structure parameters and co-former compositions. This systematic approach enables rational selection of manufacturing conditions for each form, reducing process complexity through science-based optimization rather than trial-and-error
Data Source
AI summary
The present disclosure provides crystalline forms of a JAK2 inhibitor, compositions thereof and methods of treating a JAK2-mediated disorder.